Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226035 | 0.70 | GAA (0.41) | L3MBTL1POLBMAPTTDP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10718549 | 0.68 | MEN1 (0.39) | L3MBTL1POLBMAPTTDP1ALDH1A1 | |
| SCHEMBL29412517 | 0.67 | KDM4E (0.44) | L3MBTL1GSK3BHPGDPOLBMAPT | |
| SCHEMBL14156857 | 0.66 | — | — | |
| SCHEMBL14259805 | 0.66 | L3MBTL1 (0.48) | L3MBTL1GSK3BHPGDPOLBMAPT | |
| SCHEMBL168935 | 0.66 | PDGFRA (0.52) | L3MBTL1GSK3BHPGDPOLBALDH1A1 | |
| SCHEMBL9635218 | 0.65 | L3MBTL1 (0.49) | L3MBTL1GSK3BHPGDPOLBMAPT | |
| SCHEMBL9636637 | 0.65 | L3MBTL1 (0.49) | L3MBTL1GSK3BHPGDPOLBMAPT | |
| SCHEMBL5139731 | 0.64 | KDM4E (0.43) | L3MBTL1HPGDPOLBMAPTTDP1 | |
| SCHEMBL5850195 | 0.63 | RYR2 (0.55) | L3MBTL1GSK3BHPGDPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005082873-A2 | 1,4-BENZOTHIAZEPANS AND DERIVATIVES THEREOF | BIOAGENCY AG (DE) | 2005-09-09 | — | — | WO | claimed |
| US-9770520-B2 | Chelate nanoemulsion for MRI | GUERBET (FR) | 2017-09-26 | — | — | US | disclosed |
| EP-2576536-B1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | UNIV QUEENSLAND (AU) | 2016-09-14 | — | — | EP | disclosed |
| US-9199976-B2 | Haematopoietic-prostaglandin D2 synthase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-01 | — | — | US | disclosed |
| US-20150320889-A1 | Vectorised Magnetic Emulsion | GUERBET (FR) | 2015-11-12 | — | — | US | disclosed |
| US-20130309176-A1 | CHELATE NANOEMULSION FOR MRI | UNIVERSITE DE BORDEAUX 1 (FR) | 2013-11-21 | — | — | US | disclosed |
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-30 | — | — | US | disclosed |
| EP-2576536-A2 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | The University of Queensland (AU) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150457-A2 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-12-08 | — | — | WO | disclosed |
| WO-2005113573-A2 | METHOD OF SUPPORT-BASED CHEMICAL SYNTHESIS | MIXTURE SCIENCES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261474-A1 | Method of support-based chemical synthesis | MIXTURE SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005082873-A2 | 1,4-BENZOTHIAZEPANS AND DERIVATIVES THEREOF | BIOAGENCY AG (DE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | HPGDS, PTGES, PTGIS | L3MBTL1 3610/4885GSK3B 3275/4885HPGD 9/4885 |
| US-20130309176-A1 | CHELATE NANOEMULSION FOR MRI | SGMS1, SGMS2, PHOSPHO1 | L3MBTL1 736/4885GSK3B 4751/4885HPGD 3269/4885 |
| US-20150320889-A1 | Vectorised Magnetic Emulsion | SGMS2, TFRC, SGMS1 | L3MBTL1 2628/4885GSK3B 4393/4885HPGD 3953/4885 |
| US-20050261474-A1 | Method of support-based chemical synthesis | CYP2F1, CYP4F3, CYP4F2 | L3MBTL1 3801/4885GSK3B 2272/4885HPGD 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.